Table 1 Three druggable gene targets of ALS and five existing drugs identified for drugs repurposing application. Tier 1 contains the objectives of the approved drug and clinical drug, tier 2 contains incorporated proteins closely related to drug targets or with associated drug-like compounds, and tier 3 contains incorporated extracellular proteins and members of key drug-target families [8]. All information on medications is from ChEMBL and DrugBank Online
Gene | Target | Tier of druggable genes | Tissue | Drug name | Target ChEMBL ID | Action type | Max clinical phase | Indication |
|---|---|---|---|---|---|---|---|---|
TBK1 | TANK-binding kinase 1 | Tier 1 | Blood | Fostamatinib | CHEMBL2103830 | Inhibitor | Approved | Immune thrombocytopenic purpura |
Amlexanox | NA | Inhibitor | Approved | Aphthous ulcers | ||||
TNFSF12 | Tumor necrosis factor (ligand) superfamily, member 12 | Tier 1 | Blood | BIIB-023 | CHEMBL2109598 | Antibody | 2 | Lupus nephritis; rheumatoid arthritis |
RG-7212 | CHEMBL2109600 | Antibody | 1 | Neoplasms | ||||
GPX3 | Glutathione peroxidase 3 (plasma) | Tier 1 | Blood and brain | Glutathione | CHEMBL1543 | Cofactor | 3 | Cystic fibrosis; reperfusion injury; pancreatic neoplasms; Parkinson disease; breast neoplasms; pain; peripheral nervous system diseases; Persian Gulf Syndrome |